Association of interferon regulatory factor 4 gene polymorphisms rs12203592 and rs872071 with skin cancer and haematological malignancies susceptibility: a meta-analysis of 19 case–control studies

BMC Cancer

Aihua Gu²  Peng Zhao¹  Pin Chen¹  Qing Yan¹  Songtao Wang¹ 

[1]Department of Neurosurgery, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China

[2]Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China

关键词: Cancer risk;    rs872071;    rs12203592;    Polymorphisms;    Interferon regulatory factor 4;    IRF4;    Meta-analysis;   

Others  :  858693
DOI  :  10.1186/1471-2407-14-410

 received in 2013-09-03, accepted in 2014-05-23,  发布年份 2014

【 摘 要 】

Background

Research has indicated that the rs12203592 and rs872071 interferon regulatory factor 4 (IRF4) gene polymorphisms correlate with the risk of cancer, especially skin cancer and haematological malignancies, but the results remain controversial. To understand better the effects of these two polymorphisms on skin cancer and haematological malignancies susceptibility, a cumulative meta-analysis was performed.

Methods

We conducted a search using the PubMed and Web of Science databases for relevant case-control studies published before April 2014. Summary odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were estimated using fixed- or random-effects models where appropriate. Heterogeneity test, publication bias test, and sensitivity analysis were also performed.

Results

In total, 11 articles comprised of 19 case–control studies were identified; five focused on the rs12203592 polymorphism with 7,992 cases and 8,849 controls, and six were on the rs872071 polymorphism with 3108 cases and 8300 controls. As for rs12203592, a significant correlation with overall skin cancer and haematological malignancies risk was found with the homozygote comparison model (OR = 1.566, 95% CI 1.087-2.256) and recessive model (OR = 1.526, 95% CI 1.107-2.104). For rs872071, a significantly elevated haematological malignancies risk was observed in all genetic models (homozygote comparison: OR = 1.805, 95% CI 1.402-2.323; heterozygote comparison: OR = 1.427, 95% CI 1.203-1.692; dominant: OR = 1.556, 95% CI 1.281-1.891; recessive: OR = 1.432, 95% CI 1.293-1.587; additive: OR = 1.349, 95% CI 1.201-1.515). Similarly, increased skin cancer and haematological malignancies risk was also identified after stratification of the SNP data by cancer type, ethnicity and source of controls for both polymorphisms.

Conclusions

Our meta-analysis indicated that the rs12203592 and rs872071 IRF4 gene polymorphisms are associated with individual susceptibility to skin cancer and haematological malignancies. Moreover, the effect of the rs12203592 polymorphism on skin cancer risk was particularly prominent among Caucasians. Further functional research should be performed to validate the association.

【 授权许可】

   
2014 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Bredberg A: Cancer: more of polygenic disease and less of multiple mutations? a quantitative viewpoint. Cancer 2011, 117(3):440-445.
• [2]Pharoah PD, Dunning AM, Ponder BA, Easton DF: Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004, 4(11):850-860.
• [3]Gordon R: Skin cancer: an overview of epidemiology and risk factors. Semin Oncol Nurs 2013, 29(3):160-169.
• [4]Toll A, Masferrer E, Hernandez-Ruiz ME, Ferrandiz-Pulido C, Yebenes M, Jaka A, Tuneu A, Jucgla A, Gimeno J, Baro T, Casado B, Gandarillas A, Costa I, Mojal S, Pena R, de Herreros AG, Garcia-Patos V, Pujol RM, Hernandez-Munoz I: Epithelial to mesenchymal transition markers are associated with an increased metastatic risk in primary cutaneous squamous cell carcinomas but are attenuated in lymph node metastases. J Dermatol Sci 2013, 72(2):93-102.
• [5]Saida M: Melanoma and non-melanoma skin cancers. Gan To Kagaku Ryoho 2013, 40(4):452.
• [6]Lang D, Mascarenhas JB, Shea CR: Melanocytes, melanocyte stem cells, and melanoma stem cells. Clin Dermatol 2013, 31(2):166-178.
• [7]Wong CS, Strange RC, Lear JT: Basal cell carcinoma. BMJ 2003, 327(7418):794-798.
• [8]D’Cunha N, Cobos E: An update on hematological malignancies. Tex Med 2010, 106(9):59-63.
• [9]Mitsiades CS, Anderson KC: Epigenetic modulation in hematologic malignancies: challenges and progress. J Natl Compr Canc Netw 2009, 7(Suppl 8):S1-S12. quiz S14-16
• [10]Tohda S: Overview of lymphoid neoplasms in the fourth edition of the WHO classification. Rinsho Byori 2012, 60(6):560-564.
• [11]Sabattini E, Bacci F, Sagramoso C, Pileri SA: WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 2010, 102(3):83-87.
• [12]Stevenson FK, Caligaris-Cappio F: Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004, 103(12):4389-4395.
• [13]Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61(4):212-236.
• [14]Muller AM, Ihorst G, Mertelsmann R, Engelhardt M: Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005, 84(1):1-12.
• [15]Taniguchi T, Ogasawara K, Takaoka A, Tanaka N: IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001, 19:623-655.
• [16]Mamane Y, Heylbroeck C, Genin P, Algarte M, Servant MJ, LePage C, DeLuca C, Kwon H, Lin R, Hiscott J: Interferon regulatory factors: the next generation. Gene 1999, 237(1):1-14.
• [17]Harada H, Taniguchi T, Tanaka N: The role of interferon regulatory factors in the interferon system and cell growth control. Biochimie 1998, 80(8–9):641-650.
• [18]Tamura T, Yanai H, Savitsky D, Taniguchi T: The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 2008, 26:535-584.
• [19]Matsuyama T, Grossman A, Mittrucker HW, Siderovski DP, Kiefer F, Kawakami T, Richardson CD, Taniguchi T, Yoshinaga SK, Mak TW: Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). Nucleic Acids Res 1995, 23(12):2127-2136.
• [20]Yamagata T, Nishida J, Tanaka S, Sakai R, Mitani K, Yoshida M, Taniguchi T, Yazaki Y, Hirai H: A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. Mol Cell Biol 1996, 16(4):1283-1294.
• [21]Eisenbeis CF, Singh H, Storb U: Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. Genes Dev 1995, 9(11):1377-1387.
• [22]Yanai H, Negishi H, Taniguchi T: The IRF family of transcription factors: Inception, impact and implications in oncogenesis. Oncoimmunology 2012, 1(8):1376-1386.
• [23]Zheng Y, Chaudhry A, Kas A, deRoos P, Kim JM, Chu TT, Corcoran L, Treuting P, Klein U, Rudensky AY: Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature 2009, 458(7236):351-356.
• [24]Gathany AH, Hartge P, Davis S, Cerhan JR, Severson RK, Cozen W, Rothman N, Chanock SJ, Wang SS: Relationship between interferon regulatory factor 4 genetic polymorphisms, measures of sun sensitivity and risk for non-Hodgkin lymphoma. Cancer Cause Control 2009, 20(8):1291-1302.
• [25]Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, Corda E, Randerson-Moor J, Aitken JF, Avril MF, Azizi E, Bakker B, Bianchi-Scarrà G, Bressac-de Paillerets B, Calista D, Cannon-Albright LA, Chin-A-Woeng T, Debniak T, Galore-Haskel G, Ghiorzo P, Gut I, Hansson J, Hocevar M, Höiom V, Hopper JL, Ingvar C, Kanetsky PA, Kefford RF, Landi MT, Lang J, Lubiński J, et al.: Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 2009, 41(8):920-925.
• [26]Brown KM, Macgregor S, Montgomery GW, Craig DW, Zhao ZZ, Iyadurai K, Henders AK, Homer N, Campbell MJ, Stark M, Thomas S, Schmid H, Holland EA, Gillanders EM, Duffy DL, Maskiell JA, Jetann J, Ferguson M, Stephan DA, Cust AE, Whiteman D, Green A, Olsson H, Puig S, Ghiorzo P, Hansson J, Demenais F, Goldstein AM, Gruis NA, Elder DE, et al.: Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet 2008, 40(7):838-840.
• [27]Di Bernardo MC, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, Wild R, Sullivan K, Vijayakrishnan J, Wang Y, Pittman AM, Sunter NJ, Hall AG, Dyer MJ, Matutes E, Dearden C, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Hillmen P, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Allan JM, Catovsky D, Houlston RS: A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet 2008, 40(10):1204-1210.
• [28]Shaffer AL, Emre NC, Lamy L, Ngo VN, Wright G, Xiao W, Powell J, Dave S, Yu X, Zhao H, Zeng Y, Chen B, Epstein J, Staudt LM: IRF4 addiction in multiple myeloma. Nature 2008, 454(7201):226-231.
• [29]DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
• [30]Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22(4):719-748.
• [31]Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634.
• [32]Pena-Chilet M, Blanquer-Maceiras M, Ibarrola-Villava M, Martinez-Cadenas C, Martin-Gonzalez M, Gomez-Fernandez C, Mayor M, Aviles JA, Lluch A, Ribas G: Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes associated with melanoma susceptibility in a Spanish population. BMC Cancer 2013, 13:160. BioMed Central Full Text
• [33]Qiao Y, Zhou Y, Wu C, Zhai K, Han X, Chen J, Tian X, Chang J, Lu Z, Zhang B, Yu D, Yao J, Shi Y, Tan W, Lin D: Risk of genome-wide association study-identified genetic variants for non-Hodgkin lymphoma in a Chinese population. Carcinogenesis 2013, 34(7):1516-1519.
• [34]Kvaskoff M, Whiteman DC, Zhao ZZ, Montgomery GW, Martin NG, Hayward NK, Duffy DL: Polymorphisms in nevus-associated genes MTAP, PLA2G6, and IRF4 and the risk of invasive cutaneous melanoma. Twin Res Hum Genet 2011, 14(5):422-432.
• [35]Han J, Qureshi AA, Nan H, Zhang J, Song Y, Guo Q, Hunter DJ: A germline variant in the interferon regulatory factor 4 gene as a novel skin cancer risk locus. Cancer Res 2011, 71(5):1533-1539.
• [36]Lan Q, Au WY, Chanock S, Tse J, Wong KF, Shen M, Siu LP, Yuenger J, Yeager M, Hosgood HD 3rd, Purdue MP, Liang R, Rothman N: Genetic susceptibility for chronic lymphocytic leukemia among Chinese in Hong Kong. Eur J Haematol 2010, 85(6):492-495.
• [37]Crowther-Swanepoel D, Mansouri M, Enjuanes A, Vega A, Smedby KE, Ruiz-Ponte C, Jurlander J, Juliusson G, Montserrat E, Catovsky D, Campo E, Carracedo A, Rosenquist R, Houlston RS: Verification that common variation at 2q37.1, 6p25.3, 11q24.1, 15q23, and 19q13.32 influences chronic lymphocytic leukaemia risk. Br J Haematol 2010, 150(4):473-479.
• [38]Pratt G, Fenton JA, Allsup D, Fegan C, Morgan GJ, Jackson G, Sunter NJ, Hall AG, Irving JA, Allan JM: A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma. Br J Haematol 2010, 150(3):371-373.
• [39]Broderick P, Cunningham D, Vijayakrishnan J, Cooke R, Ashworth A, Swerdlow A, Houlston R: IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma. Br J Haematol 2010, 148(3):413-415.
• [40]Wang SS, Purdue MP, Cerhan JR, Zheng T, Menashe I, Armstrong BK, Lan Q, Hartge P, Kricker A, Zhang Y, Morton LM, Vajdic CM, Holford TR, Severson RK, Grulich A, Leaderer BP, Davis S, Cozen W, Yeager M, Chanock SJ, Chatterjee N, Rothman N: Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma risk. PLoS One 2009, 4(4):e5360.
• [41]Do TN, Ucisik-Akkaya E, Davis CF, Morrison BA, Dorak MT: An intronic polymorphism of IRF4 gene influences gene transcription in vitro and shows a risk association with childhood acute lymphoblastic leukemia in males. Biochim Biophys Acta 2010, 1802(2):292-300.
• [42]Gualco G, Weiss LM, Bacchi CE: MUM1/IRF4: a review. Appl Immunohistochem Mol Morphol 2010, 18(4):301-310.
• [43]Lu R: Interferon regulatory factor 4 and 8 in B-cell development. Trends Immunol 2008, 29(10):487-492.
• [44]Klein U, Dalla-Favera R: Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol 2008, 8(1):22-33.
• [45]Sundram U, Harvell JD, Rouse RV, Natkunam Y: Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA. Mod Pathol 2003, 16(8):802-810.
• [46]Munafo M: Replication validity of genetic association studies of smoking behavior: what can meta-analytic techniques offer? Nicotine Tob Res 2004, 6(2):381-382.